Mourad Tiab

7.1k total citations
42 papers, 407 citations indexed

About

Mourad Tiab is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Mourad Tiab has authored 42 papers receiving a total of 407 indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Hematology, 17 papers in Oncology and 13 papers in Molecular Biology. Recurrent topics in Mourad Tiab's work include Multiple Myeloma Research and Treatments (28 papers), Cancer Treatment and Pharmacology (12 papers) and Protein Degradation and Inhibitors (10 papers). Mourad Tiab is often cited by papers focused on Multiple Myeloma Research and Treatments (28 papers), Cancer Treatment and Pharmacology (12 papers) and Protein Degradation and Inhibitors (10 papers). Mourad Tiab collaborates with scholars based in France, Canada and United States. Mourad Tiab's co-authors include Philippe Moreau, Françoise Méchinaud, Thierry Façon, Hervé Avet‐Loiseau, Jean‐Luc Harousseau, Xavier Leleu, Michel Attal, Laurent Garderet, Denis Caillot and Gérald Marit and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Leukemia.

In The Last Decade

Mourad Tiab

40 papers receiving 399 citations

Peers

Mourad Tiab
CL Willman United States
Nahoko Nishimoto Japan
Evelyne D’Incan France
DR Head United States
Lindsay Hladnik United States
Erica Simeone Italy
Margaret M. Showel United States
Germano Aronica Italy
Masaki Toshima Japan
Véronique Dorvaux France
CL Willman United States
Mourad Tiab
Citations per year, relative to Mourad Tiab Mourad Tiab (= 1×) peers CL Willman

Countries citing papers authored by Mourad Tiab

Since Specialization
Citations

This map shows the geographic impact of Mourad Tiab's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mourad Tiab with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mourad Tiab more than expected).

Fields of papers citing papers by Mourad Tiab

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mourad Tiab. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mourad Tiab. The network helps show where Mourad Tiab may publish in the future.

Co-authorship network of co-authors of Mourad Tiab

This figure shows the co-authorship network connecting the top 25 collaborators of Mourad Tiab. A scholar is included among the top collaborators of Mourad Tiab based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mourad Tiab. Mourad Tiab is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Touzeau, Cyrille, Aurore Perrot, Cyrille Hulin, et al.. (2024). Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma. Blood. 143(20). 2029–2036. 28 indexed citations
2.
Touzeau, Cyrille, Xavier Leleu, Mourad Tiab, et al.. (2024). All-oral triplet iberdomide, ixazomib, and dexamethasone in elderly patients with multiple myeloma at first relapse: Results of the IFM phase 2 study I2D.. Journal of Clinical Oncology. 42(16_suppl). 7507–7507. 1 indexed citations
3.
Touzeau, Cyrille, Aurore Perrot, Murielle Roussel, et al.. (2022). All-oral triplet combination of ixazomib, lenalidomide, and dexamethasone in newly diagnosed transplant-eligible multiple myeloma patients: final results of the phase II IFM 2013-06 study. Haematologica. 107(7). 1693–1697. 8 indexed citations
4.
Touzeau, Cyrille, Philippe Moreau, Aurore Perrot, et al.. (2020). Daratumumab + bortezomib, thalidomide, and dexamethasone (D-VTd) in transplant-eligible newly diagnosed multiple myeloma (TE NDMM): Baseline SLiM-CRAB based subgroup analysis of CASSIOPEIA.. Journal of Clinical Oncology. 38(15_suppl). 8538–8538. 5 indexed citations
5.
Bosch, Francesc, Guy Cantin, Agostino Cortelezzi, et al.. (2019). Obinutuzumab plus fludarabine and cyclophosphamide in previously untreated, fit patients with chronic lymphocytic leukemia: a subgroup analysis of the GREEN study. Leukemia. 34(2). 441–450. 6 indexed citations
6.
7.
8.
Magrangeas, Florence, Hervé Avet‐Loiseau, Wilfried Gouraud, et al.. (2012). Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia. 27(2). 473–481. 83 indexed citations
9.
Decaux, Olivier, Alain Renault, Véronique Sebille, et al.. (2012). Predictive Factors of Survival After Thalidomide Therapy in Advanced Multiple Myeloma: Long-Term Follow-Up of a Prospective Multicenter Nonrandomized Phase II Study in 120 Patients. Clinical Lymphoma Myeloma & Leukemia. 12(6). 418–422. 2 indexed citations
10.
Kolb, Brigitte, Cyrille Hulin, Denis Caillot, et al.. (2012). Phase I/II study of carfilzomib plus melphalan-prednisone (CMP) in elderly patients with de novo multiple myeloma.. Journal of Clinical Oncology. 30(15_suppl). 8009–8009. 14 indexed citations
11.
12.
Damaj, Gandhi, Florent Malard, Cyrille Hulin, et al.. (2011). Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program. Leukemia & lymphoma. 53(4). 632–634. 33 indexed citations
13.
Harousseau, J. L., Hervé Avet‐Loiseau, J. Y. Mary, et al.. (2010). Bortezomib Plus Dexamethasone Versus Reduced-dose Bortezomib Plus Thalidomide-dexamethasone As Induction Prior To Autologous Transplantation in Newly Diagnosed Myeloma. 95. 451. 4 indexed citations
14.
15.
Néel, A., Mourad Tiab, Grégoire Cormier, et al.. (2009). Chronic, eventually fatal, Kawasaki-like disease in an adult with spondylarthropathy responding to IVIG therapy. Joint Bone Spine. 76(5). 559–561. 3 indexed citations
16.
Grosbois, B., Éric Bellissant, Philippe Moreau, et al.. (2003). O95 Treatment of advanced multiple myeloma (MM) with thalidomide (THAL). Long term follow-up in a prospective study of 121 patients. European Journal of Internal Medicine. 14. S27–S28. 5 indexed citations
17.
Tiab, Mourad, Françoise Méchinaud, & Jean‐Luc Harousseau. (2000). Haemophagocytic syndrome associated with infections. Best Practice & Research Clinical Haematology. 13(2). 163–178. 35 indexed citations
18.
Tiab, Mourad, et al.. (1996). [Hemophagocytic syndromes. A series of 23 cases].. PubMed. 147(3). 138–44. 19 indexed citations
19.
Chevalet, P., Mourad Tiab, M. Miègeville, et al.. (1996). Infection fusariale chez le neutropénique: à propos de trois observations. La Revue de Médecine Interne. 17(6). 474–476. 5 indexed citations
20.
Raffi, F., et al.. (1990). [Empirical treatment of febrile episodes in granulocytopenic patients with a combination of piperacillin and ofloxacin. Preliminary study].. PubMed. 38(5 ( Pt 2)). 548–51. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by CL Willman Breakdown of academic impact, for papers by Nahoko Nishimoto Breakdown of academic impact, for papers by Evelyne D’Incan Breakdown of academic impact, for papers by DR Head Breakdown of academic impact, for papers by Lindsay Hladnik Breakdown of academic impact, for papers by Erica Simeone Breakdown of academic impact, for papers by Margaret M. Showel Breakdown of academic impact, for papers by Germano Aronica Breakdown of academic impact, for papers by Masaki Toshima Breakdown of academic impact, for papers by Véronique Dorvaux
Rankless by CCL
2026